Research ExplorerPublicationsRapid effect of single-dose rosiglitazone treatment on endot...

Rapid effect of single-dose rosiglitazone treatment on endothelial function in healthy men with normal glucose tolerance: data from a randomised, placebo-controlled, double-blind study.

Standard

Rapid effect of single-dose rosiglitazone treatment on endothelial function in healthy men with normal glucose tolerance: data from a randomised, placebo-controlled, double-blind study. / Walcher, Thomas; Walcher, Daniel; Hetzel, Jürgen; Mielke, Catrin; Rau, Matthias; Rittig, Kilian; Balletshofer, Bernd; Schwedhelm, Edzard; Hombach, Vinzenz; Böger, Rainer; Koenig, Wolfgang; Marx, Nikolaus.

In: DIABETES VASC DIS RE, Vol. 7, No. 3, 3, 2010, p. 178-185.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Walcher, T, Walcher, D, Hetzel, J, Mielke, C, Rau, M, Rittig, K, Balletshofer, B, Schwedhelm, E, Hombach, V, Böger, R, Koenig, W & Marx, N 2010, 'Rapid effect of single-dose rosiglitazone treatment on endothelial function in healthy men with normal glucose tolerance: data from a randomised, placebo-controlled, double-blind study.', DIABETES VASC DIS RE, vol. 7, no. 3, 3, pp. 178-185. <http://www.ncbi.nlm.nih.gov/pubmed/20460360?dopt=Citation>

APA

Walcher, T., Walcher, D., Hetzel, J., Mielke, C., Rau, M., Rittig, K., Balletshofer, B., Schwedhelm, E., Hombach, V., Böger, R., Koenig, W., & Marx, N. (2010). Rapid effect of single-dose rosiglitazone treatment on endothelial function in healthy men with normal glucose tolerance: data from a randomised, placebo-controlled, double-blind study. DIABETES VASC DIS RE, 7(3), 178-185. [3]. http://www.ncbi.nlm.nih.gov/pubmed/20460360?dopt=Citation

Vancouver

Walcher T, Walcher D, Hetzel J, Mielke C, Rau M, Rittig K et al. Rapid effect of single-dose rosiglitazone treatment on endothelial function in healthy men with normal glucose tolerance: data from a randomised, placebo-controlled, double-blind study. DIABETES VASC DIS RE. 2010;7(3):178-185. 3.

Bibtex

@article{ded4c994437f4e35b2f97ce9c2f8d855,
title = "Rapid effect of single-dose rosiglitazone treatment on endothelial function in healthy men with normal glucose tolerance: data from a randomised, placebo-controlled, double-blind study.",
abstract = "Antidiabetic thiazolidinediones (TZDs) improve endothelial function in patients with or without type 2 diabetes. The present randomised, placebo-controlled, double-blind study examined the time course of a single dose of rosiglitazone on flow-mediated endothelium-dependent vasodilation (FMD), metabolic parameters, and its effect on inflammatory markers in non-diabetic men. Forty non-obese, healthy men with normal glucose tolerance were randomised to a single dose of rosiglitazone (8 mg) or placebo, and FMD was assessed at baseline as well as after 6 h and 24 h. Rosiglitazone did not significantly affect blood glucose and insulin levels or lipid parameters after 6 and 24 h compared with placebo. Treatment with rosiglitazone significantly increased FMD after 6 h from 4.3% (3.3; 4.9) to 7.6% (5.6; 9.2) (p",
author = "Thomas Walcher and Daniel Walcher and J{\"u}rgen Hetzel and Catrin Mielke and Matthias Rau and Kilian Rittig and Bernd Balletshofer and Edzard Schwedhelm and Vinzenz Hombach and Rainer B{\"o}ger and Wolfgang Koenig and Nikolaus Marx",
year = "2010",
language = "Deutsch",
volume = "7",
pages = "178--185",
journal = "DIABETES VASC DIS RE",
issn = "1479-1641",
publisher = "SAGE Publications",
number = "3",

}

RIS

TY - JOUR

T1 - Rapid effect of single-dose rosiglitazone treatment on endothelial function in healthy men with normal glucose tolerance: data from a randomised, placebo-controlled, double-blind study.

AU - Walcher, Thomas

AU - Walcher, Daniel

AU - Hetzel, Jürgen

AU - Mielke, Catrin

AU - Rau, Matthias

AU - Rittig, Kilian

AU - Balletshofer, Bernd

AU - Schwedhelm, Edzard

AU - Hombach, Vinzenz

AU - Böger, Rainer

AU - Koenig, Wolfgang

AU - Marx, Nikolaus

PY - 2010

Y1 - 2010

N2 - Antidiabetic thiazolidinediones (TZDs) improve endothelial function in patients with or without type 2 diabetes. The present randomised, placebo-controlled, double-blind study examined the time course of a single dose of rosiglitazone on flow-mediated endothelium-dependent vasodilation (FMD), metabolic parameters, and its effect on inflammatory markers in non-diabetic men. Forty non-obese, healthy men with normal glucose tolerance were randomised to a single dose of rosiglitazone (8 mg) or placebo, and FMD was assessed at baseline as well as after 6 h and 24 h. Rosiglitazone did not significantly affect blood glucose and insulin levels or lipid parameters after 6 and 24 h compared with placebo. Treatment with rosiglitazone significantly increased FMD after 6 h from 4.3% (3.3; 4.9) to 7.6% (5.6; 9.2) (p

AB - Antidiabetic thiazolidinediones (TZDs) improve endothelial function in patients with or without type 2 diabetes. The present randomised, placebo-controlled, double-blind study examined the time course of a single dose of rosiglitazone on flow-mediated endothelium-dependent vasodilation (FMD), metabolic parameters, and its effect on inflammatory markers in non-diabetic men. Forty non-obese, healthy men with normal glucose tolerance were randomised to a single dose of rosiglitazone (8 mg) or placebo, and FMD was assessed at baseline as well as after 6 h and 24 h. Rosiglitazone did not significantly affect blood glucose and insulin levels or lipid parameters after 6 and 24 h compared with placebo. Treatment with rosiglitazone significantly increased FMD after 6 h from 4.3% (3.3; 4.9) to 7.6% (5.6; 9.2) (p

M3 - SCORING: Zeitschriftenaufsatz

VL - 7

SP - 178

EP - 185

JO - DIABETES VASC DIS RE

JF - DIABETES VASC DIS RE

SN - 1479-1641

IS - 3

M1 - 3

ER -